



Post Authorisation Assessments

Depo-Medrone V 40 mg/ml Suspension for Injection for dogs, cats, and horses Vm 42058/5161

05 November 2025	Approval of Harmonising the Adverse Events table with IE requirements.
21 October 2025	One-off alignment of the product information with version 3 of the QRD template.
14 November 2024	Change in legal entity of MA holder for UK(NI) from Zoetis UK Limited, 1st Floor, Birchwood Building Springfield Drive, Leatherhead, Surrey, KT22 7LP to Zoetis Belgium S.A., 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Co. Dublin, Ireland.
18 October 2023	Minor change to the address of the manufacturer/assembler.
12 November 2020	Decrease in batch size range of the finished product.
26 August 2020	Change in the address of the MAH from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London. EC4A 3AE to Zoetis UK Limited, 1 st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey. KT22 7LP.
03 April 2019	Addition of a new specification parameter to the specification with its corresponding test method of the finished product. Tightening of specification limits of the finished product. Addition of a new specification parameter to the specification with its corresponding test method of the finished product. Addition of a new specification parameter to the specification with its corresponding test method of the finished product. Replacement to a test procedure for the finished product. Replacement to a test procedure for the finished product. Tightening of specification limits of the finished product. Addition of a new specification parameter to the specification with its corresponding test method of the finished product.
07 December 2017	Change in the specification parameters and/or limits of the finished product.
20 July 2016	Change in the specification parameters of an active substance. Changes in the manufacturing process of the active substance.
20 May 2015	Addition of a specification parameter. Addition of alternative test methods.
21 July 2014	Change in the manufacturing process of the active substance. Change in the test procedure for the active substance.
12 February 2014	Transfer of MA from Pfizer Ltd to Zoetis UK Limited, change of distributor and change to the name of a manufacturer of the active substance.
18 January 2012	Changes to an existing pharmacovigilance system as described in the DDPS.

16 June 2009	Change of specification of the finished product.
29 July 2008	Updates to SPC and Product Literature.
13 December 2006	Change of finished product specification.
09 August 2006	Changes to the SPC and Product Literature to bring in line with new legislation.
25 April 2006	Change of MAH.
11 November 2005	Renewal.
19 October 2005	Change of batch size.
15 September 2005	Minor change of manufacturing process of the active substance. Addition of manufacturer of the active substance.
11 July 2005	Change of distributor.
28 August 2003	Change of distributor.
30 October 2001	Change of name and address of MAH.
19 July 2000	Renewal.
25 October 1999	Change of MAH name.